Mark Lampert‘s Biotechnology Value Fund recently filed a Form 13G with the SEC, in which it reported acquiring 4.58 million shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), which amass 9.99% of the company’s outstanding stock. The acquisition represents a new addition to Biotechnology Value Fund’s portfolio.
Anthera Pharmaceuticals is a biopharmaceutical company engaged in discovering and producing a variety of therapeutics to treat severe disorders. The company has two product candidates in development, and it recently reported a positive DSMB review from its Phase 3 SOLUTION Study of Sollupra™. Since the beginning of the year, the company’s stock has lost 34.05%.
bogdanhoda/Shutterstock.com
Out of the 749 hedge funds followed by Insider Monkey which filed 13Fs for the June 30 reporting period, nine investors were long Anthera Pharmaceuticals (NASDAQ:ANTH) at the end of the June quarter, down by one from the previous quarter. Some of the bullish investors contained Joseph Edelman’s Perceptive Advisors, which held a position worth $4.61 million, Kevin Kotler’s Broadfin Capital, with a position valued at $3.57 million, Kris Jenner, Gordon Bussard, Graham Mcphail’s Rock Springs Capital Management, Charles Davidson’s Wexford Capital, and Hal Mintz’ Sabby Capital.
An investor who dumped Anthera Pharmaceuticals (NASDAQ:ANTH) during the quarter was Howard Guberman’s Gruss Asset Management, which sold a position valued, at the end of March, at $2.56 million.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 0 | 0 | 0 | 0 | 0% |
| BVF Partners OS Ltd | 0 | 0 | 0 | 0 | 0 | 0% |
| BVF Partners | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
| BVF Inc | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
| Mark N. Lampert | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
Page 1 of 14 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Anthera Pharmaceuticals, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 03674U 20 1 |
| (CUSIP Number) |
| September 6, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Gaia Inc (GAIA): Ariel Investments Decreases Its Stake
Contango Oil & Gas Co (MCF): Ariel Investments Trims Its Stake
Xenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares...
Spartan Motors Inc (SPAR): Ariel Investments Lowers Its Stake
Smart & Final Stores Inc. (SFS): Glenhill Advisors Increases its Stake
Habit Restaurants Inc. (HABT): Passport Capital Adds Shares to Its Position
